Status:
UNKNOWN
Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Astellas Pharma Korea, Inc.
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
Diabetic nephropathy, the leading cause of end-stage renal disease in many countries, is characterized by high cardiovascular mortality and morbidity even in the early course of the disease. In additi...
Eligibility Criteria
Inclusion
- Aged 19 years or more and 75 years or less
- Type 2 diabetes who is prescribed glucose-lowering agent or insulin
- Estimated glomerular filtration rate (GFR) by isotope dilution mass spectrometry (IDMS)- Modification of Diet in Renal Disease (MDRD) equation 30 ml/min/1.73 m2 or more
- verified 2 times or more of albuminuria 30 mg/g cr (or protein 300 mg/g cr)or more in a spot urine sample with interval of 1 week or more in recent 6 months
- Patients whose blood pressure is 140/90 mmHg or less and did not receive a prescription for additional antihypertensive medication in recent 3 months
- Patients who give written consent to this study by oneself
Exclusion
- History of kidney transplantation
- current advanced congestive heart failure (NYHA class III or more)
- current uncontrolled arrhythmia
- current advanced liver cirrhosis (Child-Pugh class C)
- History of bleeding diathesis
- current active infection or uncontrolled inflammatory disorders
- History of cerebrovascular accident or myocardial infarction
- current use of anticoagulant
- current use of two or more antiplatelet agents
- patients with advanced malignancy (life expectancy less than 6 months)
- patients with uncontrolled diabetes (Hba1c more than 10%)
- patients with severe anemia (Hb less than 8.0 g/dL)
- female who are pregnant, trying to get pregnant or lactating
- Genetic diseases such as galactose intolerance, lactose deficiency or glucose-galactose malabsorption
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT01796418
Start Date
March 1 2013
Last Update
December 16 2013
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Hallym University Sacred Heart Hospital
Anyang, South Korea
2
Seoul National University Bundang Hospital
Seongnam, South Korea
3
Kangnam Sacred Heart Hospital
Seoul, South Korea
4
Seoul National University Boramae Medical Center
Seoul, South Korea